177 related articles for article (PubMed ID: 19941898)
1. AHR activation by tryptophan--pathogenic hallmark of Th17-mediated inflammation in eosinophilic fasciitis, eosinophilia-myalgia-syndrome and toxic oil syndrome?
Rieber N; Belohradsky BH
Immunol Lett; 2010 Feb; 128(2):154-5. PubMed ID: 19941898
[TBL] [Abstract][Full Text] [Related]
2. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
Silver RM
Curr Opin Rheumatol; 1992 Dec; 4(6):851-6. PubMed ID: 1457280
[TBL] [Abstract][Full Text] [Related]
3. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
Bolster MB; Silver RM
Curr Opin Rheumatol; 1994 Nov; 6(6):642-9. PubMed ID: 7865387
[TBL] [Abstract][Full Text] [Related]
4. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
Silver RM
Curr Opin Rheumatol; 1993 Nov; 5(6):802-8. PubMed ID: 8117543
[TBL] [Abstract][Full Text] [Related]
5. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia.
Kaufman LD; Krupp LB
Curr Opin Rheumatol; 1995 Nov; 7(6):560-7. PubMed ID: 8579979
[TBL] [Abstract][Full Text] [Related]
6. [Eosinophilia-myalgia: new syndrome].
Szechiński J; Borysewicz K
Postepy Hig Med Dosw; 1992; 46(3):319-25. PubMed ID: 1369828
[TBL] [Abstract][Full Text] [Related]
7. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins.
Veldhoen M; Hirota K; Westendorf AM; Buer J; Dumoutier L; Renauld JC; Stockinger B
Nature; 2008 May; 453(7191):106-9. PubMed ID: 18362914
[TBL] [Abstract][Full Text] [Related]
8. [Fasciitis, perimyositis, microangiopathy].
Goto K; Kumamoto T
Ryoikibetsu Shokogun Shirizu; 2001; (36):271-4. PubMed ID: 11596388
[No Abstract] [Full Text] [Related]
9. Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders.
Varga J; Kähäri VM
Curr Opin Rheumatol; 1997 Nov; 9(6):562-70. PubMed ID: 9375286
[TBL] [Abstract][Full Text] [Related]
10. Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome.
Silver RM; Sutherland SE; Carreira P; Heyes MP
J Rheumatol; 1992 Jan; 19(1):69-73. PubMed ID: 1532618
[TBL] [Abstract][Full Text] [Related]
11. The eosinophilia-myalgia syndrome and the toxic oil syndrome. Pursuing parallels.
Hertzman PA
Adv Exp Med Biol; 1996; 398():339-42. PubMed ID: 8906286
[No Abstract] [Full Text] [Related]
12. Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome.
Martínez-Cabot A; Messeguer A
Chem Res Toxicol; 2007 Oct; 20(10):1556-62. PubMed ID: 17892268
[TBL] [Abstract][Full Text] [Related]
13. [Eosinophilia myalgia syndrome (EMS) caused by L-tryptophan product and toxic oil syndrome (TOS) caused by denatured rape-seed oil].
Maitani T; Saitoh H
Shokuhin Eiseigaku Zasshi; 2009 Dec; 50(6):279-91. PubMed ID: 20065617
[No Abstract] [Full Text] [Related]
14. L-tryptophan-associated eosinophilic fasciitis prior to the 1989 eosinophilia-myalgia syndrome outbreak.
Hibbs JR; Mittleman B; Hill P; Medsger TA
Arthritis Rheum; 1992 Mar; 35(3):299-303. PubMed ID: 1536667
[TBL] [Abstract][Full Text] [Related]
15. The eosinophilia-myalgia syndrome and eosinophilic fasciitis.
Jimenez SA; Varga J
Curr Opin Rheumatol; 1991 Dec; 3(6):986-94. PubMed ID: 1772754
[TBL] [Abstract][Full Text] [Related]
16. Eosinophilia-myalgia syndrome and tryptophan production: a cautionary tale.
Mayeno AN; Gleich GJ
Trends Biotechnol; 1994 Sep; 12(9):346-52. PubMed ID: 7765187
[TBL] [Abstract][Full Text] [Related]
17. Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome.
Mayeno AN; Benson LM; Naylor S; Colberg-Beers M; Puchalski JT; Gleich GJ
Chem Res Toxicol; 1995; 8(7):911-6. PubMed ID: 8555405
[TBL] [Abstract][Full Text] [Related]
18. Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use.
Varga J; Griffin R; Newman JH; Jimenez SA
J Rheumatol; 1991 Feb; 18(2):259-63. PubMed ID: 2023221
[TBL] [Abstract][Full Text] [Related]
19. Pathogenesis of L-tryptophan eosinophilia myalgia syndrome.
Sternberg EM
Adv Exp Med Biol; 1996; 398():325-30. PubMed ID: 8906284
[TBL] [Abstract][Full Text] [Related]
20. Kynurenine 3-monooxygenase mediates inhibition of Th17 differentiation via catabolism of endogenous aryl hydrocarbon receptor ligands.
Stephens GL; Wang Q; Swerdlow B; Bhat G; Kolbeck R; Fung M
Eur J Immunol; 2013 Jul; 43(7):1727-34. PubMed ID: 23568529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
